Latest Breaking News On - Grant bogle - Page 1 : comparemela.com

Ipsen to acquire Epizyme, expanding its portfolio in oncology

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesFrance generalHong kongUnited kingdomIoana piscociuDavid loewIpsen euronextOrrick herrington sutcliffeAmerican society of clinical oncologyHealth partnersDrug administrationEpizyme incExchange commissionAmerican society of clinical oncology annual meetingCancer research united kingdomLymphoma research foundation

Epizyme (EPZM) Acquired by Ipsen for for $1 45/sh + CVRs

Epizyme (EPZM) Acquired by Ipsen for for $1 45/sh + CVRs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalHong kongUnited kingdomIoana piscociuDavid loewOrrick herrington sutcliffeAmerican society of clinical oncologyHealth partnersDrug administrationEpizyme incExchange commissionAmerican society of clinical oncology annual meetingCancer research united kingdomLymphoma research foundationWall street

Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesFrance generalHong kongUnited kingdomIoana piscociuDavid loewIpsen euronextExchange commissionAmerican society of clinical oncology annual meetingOrrick herrington sutcliffeGlobal head of franchise communications oncologyHealth partnersDrug administrationEpizyme boardsAccelerated approvalChief executive officer

Ipsen Acquires Epizyme, Expanding Portfolio in Rare Cancer Therapeutics

Ipsen Acquires Epizyme, Expanding Portfolio in Rare Cancer Therapeutics
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

David loewDrug administrationAccelerated approvalGrant bogleGreater china

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomShefali agarwalAmerican society of clinical oncologyCelgene corporationBristol myers squibbEpizyme incGroup of patients who are rituximabActivity dataStudy shows continued improvementBoth objectiveComplete responseIncludes response dataPatients who are rituximab refractoryClinical oncologyAnnual meeting